Medicus Pharma Ltd (TSE:MDCX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medicus Pharma Ltd. has entered into an agreement with Swanielle Inc. to expand its Phase 2 clinical study for Basal Cell Carcinoma into the Asia-Pacific region. The ongoing study in the U.S. has already enrolled over 25% of the expected patients, with plans for an interim data analysis in early 2025 to accelerate its development program. The company aims to transition this exploratory trial into a pivotal one, potentially fast-tracking the treatment’s clinical pathway.
For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.